Dr. Neil serves as Chief Executive Officer at Avalo Therapeutics (formerly Cerecor, Inc.), a publicly held biotechnology company since February 2022. Prior to that, Dr. Neil was Senior Scientific Adviser and Chief Scientific Officer at Avalo since Avalo’s February 2020 merger with Aevi Genomic Medicine, Inc., a biotechnology company where Dr. Neil had served as Chief Scientific Officer from September 2013 to February 2020. Prior to joining Aevi, Dr. Neil was a Partner at Apple Tree Partners, a life science private equity firm, from September 2012 to September 2013, and held a number of senior positions in the pharmaceutical industry, including most recently Corporate VP of Science & Technology at Johnson & Johnson from November 2007 to August 2012. Prior to these roles, Dr. Neil served as Group President at Johnson & Johnson Pharmaceutical Research and Development, VP of R&D at Merck KGaA/EMD Pharmaceuticals, and VP of Clinical Research at AstraZeneca and Astra Merck. Dr. Neil serves on the board of directors of Celldex Therapeuics. He also serves on the board of directors of Zura Bio Limited. Dr. Neil  served on the board of directors of Arena Pharmaceuticals, Inc. since February 2017 and as its Chair since February 2021 until it was acquired by Pfizer Inc. in March 2022. He has previously served on the board of GTx, Inc., a publicly traded biopharmaceutical company. He is a member of the board of the Center for Discovery and Innovation of the Hackensack Meridian Medical School in Hackensack, N and is the Founding Chairman of TransCelerate Biopharma, Inc., a non-profit pharmaceuticals industry R&D consortium, and is a past member of the TransCelerate Board. He served on the board of Reagan Udall Foundation for the FDA from 2007 – 2021, the board of Foundation for the National Institutes of Health (NIH) from 2010 – 2012 and on the Science Management Review Board of the NIH from 2010 - 2012. Dr. Neil is also the past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board. Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic.

Dr. Doyle is a proven research physician who brings over 20 years of experience in the pharmaceutical/biotech industry and has held numerous leadership roles in clinical development. Dr. Doyle most recently served as Chief Medical Officer at Aro Biotherapeutics. Dr. Doyle currently serves on the Board of Directors of Santa Ana Bio, and she previously served on the Board of Directors of DICE Therapeutics, until it was acquired by Eli Lilly and Company. Prior to serving as Chief Medical Officer of Aro Biotherapeutics, Dr. Doyle was Vice President, Global Therapeutic Area Head, Immunology at CSL Behring. Dr. Doyle has held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals. During her career, she has advanced assets across a broad range of immune-mediated and orphan diseases and led teams with responsibilities for design and execution of first-in-human through Phase 2 and 3 trials, resulting in several global regulatory approvals. Dr. Doyle received her BA magna cum laude from Princeton University in Romance Languages and her MD cum laude from Yale Medical School. She completed her postdoctoral training at Harvard Medical School including residency in Internal Medicine at Massachusetts General Hospital and clinical/research fellowship in Rheumatology and Immunology at Brigham and Women’s Hospital.

Mr. Sullivan most recently served as the Company’s Chief Accounting Officer and prior to that as Interim Chief Financial Officer, during which time the Company raised approximately $80 million in gross proceeds. Prior to joining Avalo, Mr. Sullivan was the Corporate Controller for Sucampo Pharmaceuticals, a Nasdaq-listed specialty pharmaceuticals company, when it was merged with Mallinckrodt in a $1.2 billion transaction. He also served as the Corporate Controller for OpGen, a Nasdaq-listed diagnostic company, and prior to that was a Senior Manager at Ernst & Young. Mr. Sullivan has a strong public company and life science background, including significant experience with equity and debt capital raises, acquisitions, divestitures, in and out-license transactions, enterprise resource planning implementations, and financial planning and analysis from leading finance and accounting functions at various public biotechnology, molecular diagnostic, and pharmaceutical companies. Mr. Sullivan received dual BS degrees in Finance and Accounting from the University of Maryland, College Park where he graduated magna cum laude, and he is a Certified Public Accountant.

Mr. Varki brings over 20 years of experience providing counsel in the pharmaceutical and biotech industry. Mr. Varki most recently served as US General Counsel at Idorsia Pharmaceuticals US Inc. Mr. Varki was previously Head of Legal at Amarin Corporation plc, SVP General Counsel, Chief Compliance Officer, and Corporate Secretary at both Braeburn Pharmaceuticals and Egalet Pharma. Prior to that, Mr. Varki spent 12 years at GSK, with increasing levels of responsibility; Counsel-US Pharmaceuticals, Senior Counsel-Global Vaccines and Biologics, and Assistant General Counsel-Global Research and Development. Mr. Varki also has prior experience practicing FDA law with Reed Smith LLP, a global private law firm in Washington DC, and as a regulatory counsel with the FDA Center for Drug Evaluation and Research (CDER). He earned his J.D. from Temple University School of Law, earned his Master of Public Health (M.P.H.) from George Washington University School of Public Health and received his Bachelor’s degree from the College of William and Mary.

Dr. Hegg brings over 20 years of Research and Development (R&D) and leadership experience to Avalo Therapeutics as Senior Vice President, Program Management and Corporate Infrastructure. Prior to joining the company, Dr. Hegg served as Vice President, Development and Project Management at Aclaris Therapeutics, where she led dermatology and immune-inflammation early- and mid-stage development programs. Prior to Aclaris, Dr. Hegg held the role of VP, Head of Project and Planning & Management as well as Medicine Development Leader at GlaxoSmithKline (GSK) where she oversaw multidisciplinary teams through early- and late-stage drug development, market launch, and postapproval processes. Following her postdoctoral fellowship at the University of Massachusetts Medical Center, Dr. Hegg began her industry career at GSK in R&D Discovery where she held significant project management and leadership roles in cardiovascular, metabolic, pulmonary, immuno-inflammatory, dermatology, and urogenital programs/products. Dr. Hegg received her BS from Muhlenberg College and her PhD from Clark University.

Ms. Matkowski brings over 25 years of biopharmaceutical industry regulatory experience to Avalo as Senior Vice President, Global Regulatory Affairs and Quality Assurance. Prior to joining Avalo, she was a Senior Global Regulatory Consultant for large and small pharmaceutical companies, where she focused primarily on the development of therapies for rare diseases. Ms. Matkowski was the Head of Regulatory Affairs at Aclaris Therapeutics, where she led multiple global programs throughout development. She has held various regulatory positions across multiple therapeutic areas at Takeda, BioMarin, ViroPharma, Endo Pharmaceuticals, Cephalon, and Wyeth Pharmaceuticals. Ms. Matkowski began her career at the Food and Drug Administration (FDA), where she served in various roles within the Office of Regulatory Affairs (ORA), Philadelphia District. Ms. Matkowski received her BS in Public Health from The Richard Stockton College of New Jersey, as well as an MS in Pharmaceutical Regulatory Affairs/Quality Assurance from Temple University.

Dr. Dino Miano brings more than 25 years of experience in pharmaceutical development in areas of analytical and product development, and manufacturing.  Prior to joining Avalo Therapeutics, Dr. Miano served as an Executive Director at Alexion Pharmaceuticals where he spent most of his career leading the analytical and pharmaceutical development groups.  Under his leadership, his teams provided analytical, formulation, and stability support to all areas of the organization including process development, devices, manufacturing, and quality control.  Dr. Miano was a key partner of Global Operations in delivering clinical material from early-stage programs through commercialization.  During his tenure at Alexion, Dr. Miano was an integral part in the clinical development and global commercialization of Soliris^®, Strensiq^®, Kanuma^® and Ultomiris^® therapies for rare disease indications.  He was appointed the cross functional leader for Ultomiris^® responsible for delivering drug product throughout the clinical phases of development.  His work also included supporting over 20 clinical novel biologics programs for analytical and formulation development.  Dr. Miano completed his postdoctoral training at the RW Johnson Research Institute.  Dr. Miano holds a BSc in Chemistry/Biology from University of Hartford, and a PhD in Chemistry/Biochemistry from University of Massachusetts.